News

Cartherics and panCELLa announce collaborative agreement to develop pluripotent cell lines for cell therapy

13 February 2019  Cartherics and panCELLa are pleased to announce their collaboration to research, develop and commercialise products for the treatment of cancer and other debilitating diseases using cell therapy. panCELLa will integrate their exclusive FailSafeTM technology into Cartherics’ proprietary…

Nucleus Network expands early phase trial capacity in Australia with acquisition of Q-Pharm

11 February 2019 Nucleus Network recently announced its acquisition of Q-Pharm, a 62-bed dedicated early-phase clinical trial facility based in the Herston health precinct in Brisbane. Q-Pharm was previously wholly owned by the QIMR Berghofer Medical Research Institute.…

4th Annual CEO Remuneration Report – Wexford Hayes

31 January 2019 This 4th annual CEO Remuneration report reviews the remuneration of the top 100 public companies listed on the Australian Securities Exchange for the Health Care & Biotechnology Sector. The report provides insight into remuneration in…

25-27 March 2020 – Eradicate Cancer ‘How well is immunotherapy winning?’

25-27 March 2020 Melbourne Convention and Exhibition Centre “Success Breeds Success” The field of immunotherapy against cancers is making unprecedented progress. The Eradicate Cancer Conference “Can advanced immunotherapy make it possible?” held in March 2018 was a resounding success.…

Sienna furthers its Global Expansion with Distributor for the Republic of Korea

22 January 2019 Highlights: Mirax Corporation appointed as exclusive distributor for Korea Important expansion of commercial opportunity in high-growth Asian IVD market Sienna Cancer Diagnostics Ltd a medical technology company developing and commercialising innovative cancer related tests, continues…

Super Charging The Immune System to Fight Cancer

22 January 2019 Innovative immunotherapies for cancer are a step closer to reality thanks to an agreement between Australia’s Cartherics Pty Ltd and Seoul-based ToolGen Inc. The agreement, signed in Melbourne on 21 January 2019, enables the companies…

Imagion Biosystems teams with Planet Innovation for MagSense™ instrument development

MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, and Planet Innovation, a healthtech innovation and commercialization company, are pleased to announce that they have entered into a…

Victoria leads the way with NHMRC funding

13 December 2018  The announcement of the latest round of NHMRC funding yesterday has again highlighted the strength of Melbourne’s medical research community. Continuing the state’s unbroken record of receiving more than 40% of NHMRC competitive grant funding,…

Design + Industry is now ISO 13485:2016 certified

BioMelbourne Network member Design + Industry (D+I) is proud to announce that they have achieved ISO 13485:2016 certification — the culmination of a four-year effort and recognition of their commitment to design and engineering excellence in the development…

Nominations open for 2019 Women in Leadership Awards

Do you know a woman who is making an outstanding contribution to the health and biotech sector? Why not nominate her for a 2019 BioMelbourne Network Women in Leadership Award? Awards are made in three categories, recognising women in…

Board announcement: CEO resignation

6 December 2018 Message from the Chair On behalf of the Board of BioMelbourne Network, I advise our Members, partners and associates that our CEO, Dr Krystal Evans, has tendered her resignation. Krystal will leave us in the…

2019 ARCS Annual Conference: call for session and program proposals extended

Interested parties from industry, research institutions, government and academia involved in development through to commercialisation of therapeutics (from bench to bedside) are invited to submit session proposals and program suggestions for the 2019 ARCS Annual Conference to be…

Home

News & opinion

Member Directory

Events